株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

内皮機能不全:パイプライン製品の分析

Endothelial Dysfunction - Pipeline Review, H2 2014

発行 Global Markets Direct 商品コード 302500
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
内皮機能不全:パイプライン製品の分析 Endothelial Dysfunction - Pipeline Review, H2 2014
出版日: 2014年11月14日 ページ情報: 英文 32 Pages
概要

内皮機能不全とは、血管の内皮(内壁)が正常に機能しない状態です。症状には、胸の痛み、圧迫感・不快感、息切れ、異常な倦怠感、エネルギー不足、睡眠障害などが含まれます。

当レポートでは、内皮機能不全に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

内皮機能不全の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Johnson & Johnson
  • 中外製薬
  • Glucox Biotech AB
  • Stealth Peptides Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • MTP-131
  • maxacalcitol
  • Gene Therapy for Arteriosclerosis and Endothelial Dysfunction
  • S-adenosyl methionine
  • Small Molecule To Inhibit NOX-4 For Endothelial Dysfunction
  • MC-1575

パイプライン製品の最新動向

休止状態のプロジェクト

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC5774IDB

Summary

Global Markets Direct's, 'Endothelial Dysfunction - Pipeline Review, H2 2014', provides an overview of the Endothelial Dysfunction's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Endothelial Dysfunction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endothelial Dysfunction and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Endothelial Dysfunction
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Endothelial Dysfunction and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Endothelial Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Endothelial Dysfunction pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Endothelial Dysfunction
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Endothelial Dysfunction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Endothelial Dysfunction Overview
  • Therapeutics Development
    • Pipeline Products for Endothelial Dysfunction - Overview
    • Pipeline Products for Endothelial Dysfunction - Comparative Analysis
  • Endothelial Dysfunction - Therapeutics under Development by Companies
  • Endothelial Dysfunction - Therapeutics under Investigation by Universities/Institutes
  • Endothelial Dysfunction - Pipeline Products Glance
    • Early Stage Products
  • Endothelial Dysfunction - Products under Development by Companies
  • Endothelial Dysfunction - Products under Investigation by Universities/Institutes
  • Endothelial Dysfunction - Companies Involved in Therapeutics Development
    • Chugai Pharmaceutical Co., Ltd.
    • Glucox Biotech AB
    • Johnson & Johnson
  • Endothelial Dysfunction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Molecule Type
  • Drug Profiles
    • Gene Therapy for Arteriosclerosis and Endothelial Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • maxacalcitol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OX-029 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Activate HO-1 for Endothelial Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NOX-4 for Endothelial Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Endothelial Dysfunction - Dormant Projects
  • Endothelial Dysfunction - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Endothelial Dysfunction, H2 2014
  • Number of Products under Development for Endothelial Dysfunction - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Number of Products under Investigation by Universities/Institutes, H2 2014
  • Comparative Analysis by Early Stage Development, H2 2014
  • Products under Development by Companies, H2 2014
  • Products under Investigation by Universities/Institutes, H2 2014
  • Endothelial Dysfunction - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2014
  • Endothelial Dysfunction - Pipeline by Glucox Biotech AB, H2 2014
  • Endothelial Dysfunction - Pipeline by Johnson & Johnson, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Stage and Target, H2 2014
  • Number of Products by Stage and Mechanism of Action, H2 2014
  • Number of Products by Stage and Molecule Type, H2 2014
  • Endothelial Dysfunction - Dormant Projects, H2 2014
  • Endothelial Dysfunction - Discontinued Products, H2 2014

List of Figures

  • Number of Products under Development for Endothelial Dysfunction, H2 2014
  • Number of Products under Development for Endothelial Dysfunction - Comparative Analysis, H2 2014
  • Number of Products under Development by Companies, H2 2014
  • Comparative Analysis by Early Stage Products, H2 2014
  • Assessment by Monotherapy Products, H2 2014
  • Number of Products by Top 10 Targets, H2 2014
  • Number of Products by Stage and Top 10 Targets, H2 2014
  • Number of Products by Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014
  • Number of Products by Top 10 Molecule Types, H2 2014
  • Number of Products by Stage and Top 10 Molecule Types, H2 2014
Back to Top